ReachRxResearch
Home
Research
Sign Up
Anti-PLA2R Positivity Does Not Exclude Malignancy in Membranous Nephropathy: Lessons from the Course After Tumor Treatment
Back to Research Hub
  1. Home
  2. Research Hub
  3. Anti-PLA2R Positivity Does Not Exclude M…

Anti-PLA2R Positivity Does Not Exclude Malignancy in Membranous Nephropathy: Lessons from the Course After Tumor Treatment

Clinical Kidney Journal·October 7Open Access
Urology & NephrologyPractice changingMalignancy-Associated NephropathyMembranous NephropathyCase SeriesTumor TreatmentAdultAnti-PLA2R Antibody

Summary

View source

What was studied

Whether anti-PLA2R antibody positivity can reliably exclude malignancy as the underlying cause in patients with membranous nephropathy (MN), evaluated through clinical outcomes after tumor treatment.

Key findings

Anti-PLA2R positivity does not exclude malignancy-associated membranous nephropathy; some patients with detectable anti-PLA2R antibodies had remission of MN following tumor treatment, indicating a paraneoplastic etiology despite PLA2R seropositivity.

Study limitations

Likely a small case series or retrospective cohort, which limits generalizability; causality between tumor treatment and MN remission is difficult to establish definitively without controlled comparisons.

Clinical implications

Clinicians should not use anti-PLA2R positivity alone to rule out cancer-associated membranous nephropathy — a thorough malignancy workup remains important even when PLA2R antibodies are detected.

Caveats

  • The finding challenges the widely held clinical assumption that anti-PLA2R positivity indicates primary (idiopathic) MN and excludes secondary causes — clinicians should revisit this heuristic in their practice
  • The mechanism by which tumors may drive anti-PLA2R antibody production is not fully established, adding biological uncertainty to the clinical conclusions
  • The study likely involves a small number of cases, so findings should be interpreted cautiously and not over-extrapolated to all PLA2R-positive MN patients

Related Questions

Explore related topics

How should I work up membranous nephropathy for underlying malignancy in clinical practice?Can PLA2R-positive membranous nephropathy be paraneoplastic?What cancers are most commonly associated with membranous nephropathy?

Publication Details

Year
2026
Journal
Clinical Kidney Journal
Source
View article
Keep scrolling
More content below.
Up Next